Jessica Geiger, MD, medical oncologist, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, discusses challenges with the patient population enrolled in the phase III KEYNOTE-630 trial exploring the use of adjuvant pembrolizumab (Keytruda) in cutaneous squamous cell carcinoma.
